Mapping the single-cell landscape of acral melanoma and analysis of the molecular regulatory network of the tumor microenvironments

  1. Zan He
  2. Zijuan Xin
  3. Qiong Yang
  4. Chen Wang
  5. Meng Li
  6. Wei Rao
  7. Zhimin Du
  8. Jia Bai
  9. Zixuan Guo
  10. Xiuyan Ruan
  11. Zhaojun Zhang
  12. Xiangdong Fang  Is a corresponding author
  13. Hua Zhao  Is a corresponding author
  1. General Hospital of People's Liberation Army, China
  2. Chinese Academy of Sciences, China

Abstract

Acral melanoma (AM) exhibits a high incidence in Asian patients with melanoma, and it is not well treated with immunotherapy. However, little attention has been paid to the characteristics of the immune microenvironment in AM. Therefore, in this study, we collected clinical samples from Chinese patients with AM and conducted single-cell RNA sequencing to analyze the heterogeneity of its tumour microenvironments (TMEs) and the molecular regulatory network . Our analysis revealed that genes, such as TWIST1, EREG, TNFRSF9, and CTGF could drive the deregulation of various TME components. The molecular interaction relationships between TME cells, such as MIF-CD44 and TNFSF9-TNFRSF9, might be an attractive target for developing novel immunotherapeutic agents.

Data availability

Sequencing data have been deposited in GSA under accession codes HRA001804.

The following data sets were generated
The following previously published data sets were used

Article and author information

Author details

  1. Zan He

    Department of Dermatology, General Hospital of People's Liberation Army, Beijing, China
    Competing interests
    The authors declare that no competing interests exist.
  2. Zijuan Xin

    Beijing Institute of Genomics, Chinese Academy of Sciences, Beijing, China
    Competing interests
    The authors declare that no competing interests exist.
  3. Qiong Yang

    Beijing Institute of Genomics, Chinese Academy of Sciences, Beijing, China
    Competing interests
    The authors declare that no competing interests exist.
  4. Chen Wang

    Beijing Institute of Genomics, Chinese Academy of Sciences, Beijing, China
    Competing interests
    The authors declare that no competing interests exist.
  5. Meng Li

    Beijing Institute of Genomics, Chinese Academy of Sciences, Beijing, China
    Competing interests
    The authors declare that no competing interests exist.
  6. Wei Rao

    Department of Dermatology, General Hospital of People's Liberation Army, Beijing, China
    Competing interests
    The authors declare that no competing interests exist.
  7. Zhimin Du

    Department of Dermatology, General Hospital of People's Liberation Army, Beijing, China
    Competing interests
    The authors declare that no competing interests exist.
  8. Jia Bai

    Department of Dermatology, General Hospital of People's Liberation Army, Beijing, China
    Competing interests
    The authors declare that no competing interests exist.
  9. Zixuan Guo

    Department of Dermatology, General Hospital of People's Liberation Army, Beijing, China
    Competing interests
    The authors declare that no competing interests exist.
  10. Xiuyan Ruan

    Beijing Institute of Genomics, Chinese Academy of Sciences, Beijing, China
    Competing interests
    The authors declare that no competing interests exist.
  11. Zhaojun Zhang

    Beijing Institute of Genomics, Chinese Academy of Sciences, Beijing, China
    Competing interests
    The authors declare that no competing interests exist.
  12. Xiangdong Fang

    Beijing Institute of Genomics, Chinese Academy of Sciences, Beijing, China
    For correspondence
    fangxd@big.ac.cn
    Competing interests
    The authors declare that no competing interests exist.
  13. Hua Zhao

    Department of Dermatology, General Hospital of People's Liberation Army, Beijing, China
    For correspondence
    hualuck301@163.com
    Competing interests
    The authors declare that no competing interests exist.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0001-7139-1844

Funding

National Natural Science Foundation of China (81672698)

  • Hua Zhao

The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.

Ethics

Human subjects: All samples were obtained from the General Hospital of the People's Liberation Army, Beijing, China. All volunteers signed informed consent prior to sample acquisition. Four primary AM tissues, three paracancerous tissues, and a metastatic lymph gland sample were included in this cohort. This study was approved by the Ethics Committee of Chinese PLA General Hospital and complied with all relevant ethical regulations(Approval No. S2021-626).

Copyright

© 2022, He et al.

This article is distributed under the terms of the Creative Commons Attribution License permitting unrestricted use and redistribution provided that the original author and source are credited.

Metrics

  • 2,328
    views
  • 470
    downloads
  • 15
    citations

Views, downloads and citations are aggregated across all versions of this paper published by eLife.

Download links

A two-part list of links to download the article, or parts of the article, in various formats.

Downloads (link to download the article as PDF)

Open citations (links to open the citations from this article in various online reference manager services)

Cite this article (links to download the citations from this article in formats compatible with various reference manager tools)

  1. Zan He
  2. Zijuan Xin
  3. Qiong Yang
  4. Chen Wang
  5. Meng Li
  6. Wei Rao
  7. Zhimin Du
  8. Jia Bai
  9. Zixuan Guo
  10. Xiuyan Ruan
  11. Zhaojun Zhang
  12. Xiangdong Fang
  13. Hua Zhao
(2022)
Mapping the single-cell landscape of acral melanoma and analysis of the molecular regulatory network of the tumor microenvironments
eLife 11:e78616.
https://doi.org/10.7554/eLife.78616

Share this article

https://doi.org/10.7554/eLife.78616

Further reading

    1. Cancer Biology
    Han V Han, Richard Efem ... Richard Z Lin
    Research Article

    Most human pancreatic ductal adenocarcinoma (PDAC) are not infiltrated with cytotoxic T cells and are highly resistant to immunotherapy. Over 90% of PDAC have oncogenic KRAS mutations, and phosphoinositide 3-kinases (PI3Ks) are direct effectors of KRAS. Our previous study demonstrated that ablation of Pik3ca in KPC (KrasG12D; Trp53R172H; Pdx1-Cre) pancreatic cancer cells induced host T cells to infiltrate and completely eliminate the tumors in a syngeneic orthotopic implantation mouse model. Now, we show that implantation of Pik3ca−/− KPC (named αKO) cancer cells induces clonal enrichment of cytotoxic T cells infiltrating the pancreatic tumors. To identify potential molecules that can regulate the activity of these anti-tumor T cells, we conducted an in vivo genome-wide gene-deletion screen using αKO cells implanted in the mouse pancreas. The result shows that deletion of propionyl-CoA carboxylase subunit B gene (Pccb) in αKO cells (named p-αKO) leads to immune evasion, tumor progression, and death of host mice. Surprisingly, p-αKO tumors are still infiltrated with clonally enriched CD8+ T cells but they are inactive against tumor cells. However, blockade of PD-L1/PD1 interaction reactivated these clonally enriched T cells infiltrating p-αKO tumors, leading to slower tumor progression and improve survival of host mice. These results indicate that Pccb can modulate the activity of cytotoxic T cells infiltrating some pancreatic cancers and this understanding may lead to improvement in immunotherapy for this difficult-to-treat cancer.

    1. Cancer Biology
    2. Immunology and Inflammation
    Almudena Mendez-Perez, Andres M Acosta-Moreno ... Esteban Veiga
    Short Report

    In this study, we present a proof-of-concept classical vaccination experiment that validates the in silico identification of tumor neoantigens (TNAs) using a machine learning-based platform called NAP-CNB. Unlike other TNA predictors, NAP-CNB leverages RNA-seq data to consider the relative expression of neoantigens in tumors. Our experiments show the efficacy of NAP-CNB. Predicted TNAs elicited potent antitumor responses in mice following classical vaccination protocols. Notably, optimal antitumor activity was observed when targeting the antigen with higher expression in the tumor, which was not the most immunogenic. Additionally, the vaccination combining different neoantigens resulted in vastly improved responses compared to each one individually, showing the worth of multiantigen-based approaches. These findings validate NAP-CNB as an innovative TNA identification platform and make a substantial contribution to advancing the next generation of personalized immunotherapies.